Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension

Chest

Volumn 144, Issue 2, 2013, Pages 531-541

  Sadoughi, Ali ^a   Roberts, Kari E ^b   Preston, Ioana R ^b   Lai, Ginny P ^c   McCollister, Deborah H ^d   Farber, Harrison W ^e   Hill, Nicholas S ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c ICON Late Phase and Outcomes Research   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; DESVENLAFAXINE; DIGOXIN; DIURETIC AGENT; DOXEPIN; DULOXETINE; ENDOTHELIN RECEPTOR ANTAGONIST; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; OXYGEN; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRAZODONE; VENLAFAXINE; WARFARIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE EXACERBATION; DISEASE REGISTRY; DRUG USE; EXPLORATORY RESEARCH; FEMALE; HIGH RISK PATIENT; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT RESPONSE;

EID: 84881535681     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2081     Document Type: Article

References (36)

1. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med. 2003; 168 (4): 487-493.
2. Kay JM, Crawford N, Heath D. Blood 5-hydroxytryptamine in rats with pulmonary hypertension produced by ingestion of Crotalaria spectabilis seeds. Experientia. 1968; 24 (11): 1149-1150.
3. Abenhaim L, Moride Y, Brenot F, et al; International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996; 335 (9): 609-616.
4. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfl uramine, and chlorphentermine are serotonin trans porter substrates. Implications for primary pulmonary hypertension. Circulation. 1999; 100 (8): 869-875.
5. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995; 99 (3): 249-254.
6. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 2000; 131 (2): 161-168.
7. Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol. 1997; 272 (5 pt 1): L795-L806.
8. Welsh DJ, Harnett M, MacLean M, Peacock AJ. Proliferation and signaling in fi broblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med. 2004; 170 (3): 252-259.
9. Dempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol. 2008; 155 (4): 455-462.
10. McMahon TJ, Hood JS, Nossaman BD, Kadowitz PJ. Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J Appl Physiol. 1993; 75 (1): 93-102.
11. Morecroft I, Loughlin L, Nilsen M, et al. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther. 2005; 313 (2): 539-548.
12. Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000; 105 (11): 1555-1562.
13. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001; 108 (8): 1141-1150.
14. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005; 111 (21): 2812-2819.
15. Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003; 108 (15): 1839-1844.
16. Slattery DA, Hudson AL, Nutt DJ. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol. 2004; 18 (1): 1-21.
17. Eddahibi S, Fabre V, Boni C, et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res. 1999; 84 (3): 329-336.
18. Kawut SM, Horn EM, Berekashvili KK, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arte rial hypertension. Pulm Pharmacol Ther. 2006; 19 (5): 370-374.
19. Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest. 2009; 136 (3): 694-700.
20. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006; 354 (6): 579-587.
21. Dhalla IA, Juurlink DN, Gomes T, Granton JT, Zheng H, Mamdani MM. Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: a case-control study. Chest. 2012; 141 (2): 348-353.
22. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010; 137 (2): 376-387.
23. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008; 83 (8): 923-931.
24. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003; 108 (1): 32-36.
25. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profi le of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997; 340 (2-3): 249-258.
26. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fl uoxetine. Biol Psychiatry. 2001; 50 (5): 345-350.
27. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164-172.
28. McCollister DH, Beutz M, McLaughlin V, et al. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010; 51(4):339-339.e8.
29. Sclar DA, Robison LM, Skaer TL. Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United States. Int Clin Psychopharmacol. 2008; 23(2): 106-109.
30. Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001; 161 (14): 1725-1730.
31. Wellenius GA, Mukamal KJ, Kulshreshtha A, Asonganyi S, Mittleman MA. Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts. Circulation. 2008; 117 (18): 2313-2319.
32. Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symp toms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA. 2008; 300 (20): 2379-2388.
33. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67(5): 446-457.
34. Conboy L, Varea E, Castro JE, et al. Macrophage migration inhibitory factor is critically involved in basal and fl uoxetinestimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol Psychiatry. 2011; 16 (5): 533-547.
35. Hassoun PM, Mouthon L, Barberà JA, et al. Infl ammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009; 54 (suppl 1): S10-S19.
36. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor-and imipramine-controlled trials. J Clin Psychiatry. 2001; 62 (4): 256-260.